Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Enorama Pharma

2.41 SEK

-2.82 %

Less than 1K followers

ERMA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.82 %
-13.93 %
-19.67 %
-3.21 %
-28.27 %
-25.85 %
-29.58 %
-91.76 %
-62.15 %

Enorama Pharma is a pharmaceutical company. The company's operations are focused on producing and developing medical nicotine chewing gum. The products are sold mainly through retailers who sell the product under their own brand. The largest market is found in the Nordic region, but with a share of sales exported globally. Enorama Pharma was founded in 2006 and the headquarters are located in Malmö.

Read more
Market cap
179.76M SEK
Turnover
4.77K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release12/2/2025, 1:30 PM

Enorama Pharma: BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN ENORAMA PHARMA AB (PUBL)

Enorama Pharma
Regulatory press release11/12/2025, 3:00 PM

Notice of extraordinary general meeting in Enorama Pharma AB (publ)

Enorama Pharma
Regulatory press release9/25/2024, 10:00 AM

Enorama Pharma AB (publ) Explores Divestment of Nicotine Replacement Therapy Chewing Gum Business

Enorama Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.